Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: J Dermatol. 2012 Apr 9;39(7):617–624. doi: 10.1111/j.1346-8138.2012.01553.x

Figure 2. A single treatment with decitabine is sufficient to allow expression of the endogenous Oct4 protein in HSKs.

Figure 2

A) Immunofluorescent image of Oct4 expression in HSKs treated with one dose of 25 μM Decitabine for 48 hours. B) Immunofluorescent image of Oct4 expression in HSKs transfected with pMSCV-OCT4 for 48 hours. Note, transfection hits only ~10% of HSKs, and these cells have extremely high expression of nuclear Oct4. Decitabine treatment affects 96% of HSKs, and these cells show a low expression of Oct4. Blue = DAPI. Red/pink = antibody to Oct4.